Vanuatu Economic Times
SEE OTHER BRANDS

News on business and economy in Vanuatu

Vanuatu Economic Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Economic Times.

Press releases published on April 30, 2025

Der 798 Art District und das Beijing International Film Festival präsentieren gemeinsam „Art Lights the Screen“ – ein Film- und Kunstfestival

Der 798 Art District und das Beijing International Film Festival präsentieren gemeinsam „Art Lights the Screen“ – ein Film- und Kunstfestival

PEKING, April 30, 2025 (GLOBE NEWSWIRE) -- Der 798 Art District und das 15. Beijing International Film Festival (Internationale Filmfestival Beijing) haben offiziell die Veranstaltungsreihe „Art Lights the Screen" (Kunst erhellt die Leinwand) eröffnet, die …

798 Art District et le Festival international du film de Pékin lancent conjointement « Art Lights the Screen », une fête culturelle dédiée au cinéma et à l’art

798 Art District et le Festival international du film de Pékin lancent conjointement « Art Lights the Screen », une fête culturelle dédiée au cinéma et à l’art

PÉKIN, 30 avr. 2025 (GLOBE NEWSWIRE) -- 798 Art District et le 15e Festival international du film de Pékin ont officiellement lancé l’événement « Art Lights the Screen » (L’art illumine l’écran), qui aura lieu jusqu’au 5 mai. S’étendant sur 520 000 m² au …

CMB.TECH BUSINESS UPDATE

CMB.TECH BUSINESS UPDATE

Antwerp, April 30, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT …

High Arctic Overseas Announces 2024 Fourth Quarter Results

High Arctic Overseas Announces 2024 Fourth Quarter Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- High Arctic ‎ …

  Stellantis Reports Q1 2025 Net Revenues and Shipments

Stellantis Reports Q1 2025 Net Revenues and Shipments

Stellantis Reports Q1 2025 Net Revenues and Shipments Net revenues of €35.8 billion, down 14% compared to Q1 2024 primarily due to lower shipment volumes, as well as unfavorable mix and pricing Consolidated shipments(1) of 1,217 thousand units, down 9%, …

Cabka Receives B Score in Second CDP Climate Assessment

Cabka Receives B Score in Second CDP Climate Assessment

PRESS RELEASE Amsterdam April 30, 2025. Cabka N.V. (together with its subsidiaries “Cabka”, or the “Company”), a company specialized in transforming hard-to-recycle plastic waste into innovative Reusable Transport Packaging (RTP), listed at Euronext …

Audited Results for the year ended 31 December 2024

Audited Results for the year ended 31 December 2024

Audited Results for the year ended 31 December 2024 Serabi Gold plc (“Serabi” or the “Company”) (AIM:SRB, TSX:SBI, OTCQX:SRBIF), the Brazilian focused gold mining and development company, is pleased to announce the Company’s audited results for the year …

Veriff and Legitify Partner to Streamline Cross-Border Digital Notarisation

Veriff and Legitify Partner to Streamline Cross-Border Digital Notarisation

London, April 30, 2025 (GLOBE NEWSWIRE) -- Veriff, a global AI-native identity verification company powering trust infrastructure online, today announced its partnership with Legitify, an innovative platform that simplifies the online notarisation process. …

Galantas Report Financial Results for the Year Ended December 31, 2024

Galantas Report Financial Results for the Year Ended December 31, 2024

TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Galantas Gold Corporation (TSX-V …

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by …

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast

Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast

L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement avancé ou à la limite de la résécabilité …

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune checkpoint. Potential of signature to enhance …

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard  - Au congrès annuel de l’AACR 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025

Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique aux points de contrôle immunitaires …

Nicox : Résultats financiers de l’année 2024

Nicox : Résultats financiers de l’année 2024

Chiffre d’affaires de Nicox SA de 7,9 millions d’euros pour l’année 2024  Produits exceptionnels de 13,7 millions d’euros suite à la cession du flux futur de redevances de VYZULTA au fond Soleus Capital Trésorerie de Nicox SA au 31 décembre 2024 de 10,5 …

Technip Energies First Quarter 2025 Financial Results

Technip Energies First Quarter 2025 Financial Results

TECHNIP ENERGIES Q1 2025 FINANCIAL RESULTS A strong company in any scenario         Significant growth in the first quarter: Revenue +22% Y/Y to €1.85bn and Recurring EBITDA +19% Y/Y €162m 2025 Group guidance confirmed with segment revenues updated and …

Resultats Financiers de Technip Energies du Premier Trimestre 2025

Resultats Financiers de Technip Energies du Premier Trimestre 2025

RÉSULTATS FINANCIERS DE TECHNIP ENERGIES DU PREMIER TRIMESTRE 2025 Une entreprise solide quel que soit le scénario         Forte croissance au premier trimestre : chiffre d'affaires en hausse de 22 % à 1,85 milliard d'euros et EBITDA récurrent en hausse de …

Nicox Provides Full Year 2024 Financial Results

Nicox Provides Full Year 2024 Financial Results

Nicox SA revenue of €7.9 million for full year 2024  Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus Capital Nicox SA cash of €10.5 million on 31 December 2024 and the Company estimates it is …

Port Access Approval Received as Last Key Item for FID at Minim Martap Bauxite Project

Port Access Approval Received as Last Key Item for FID at Minim Martap Bauxite Project

Highlights: With port access approval in place, detailed design for bauxite port loading infrastructure has now commenced Final tenders received for mine development and road access upgrade to Inland Rail Facility (IRF) Engineering design of IRF …

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO New recruits expand senior team capabilities as the business progresses its lead HDAC6 inhibitor program, AGT-100216, into the clinic for the …

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service